TDMS Study 89006-04 Pathology Tables
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
CORE STUDY
Facility: Southern Research Institute
Chemical CAS #: 30516-871
Lock Date: 11/01/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 8 7 6 8
Natural Death 5 5 6 9
Dosing Accident 2
Accidently Killed 1
Survivors
Terminal Sacrifice 37 37 36 32
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (47) (47) (48) (45)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Intestine Large, Colon (49) (49) (48) (47)
Intestine Small, Jejunum (47) (46) (46) (45)
Intestine Small, Ileum (47) (46) (46) (45)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 9 (18%) 12 (24%) 11 (22%) 10 (20%)
Hepatocellular Carcinoma, Multiple 5 (10%) 3 (6%) 3 (6%) 2 (4%)
Hepatocellular Adenoma 16 (32%) 6 (12%) 11 (22%) 9 (18%)
Hepatocellular Adenoma, Multiple 3 (6%) 4 (8%) 3 (6%) 6 (12%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma 1 (2%)
Mesentery (10) (12) (9) (10)
Fibrous Histiocytoma 1 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (10%)
Histiocytic Sarcoma 1 (10%)
Sarcoma 1 (11%)
Pancreas (48) (50) (50) (49)
Fibrous Histiocytoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma 1 (2%)
Salivary Glands (50) (49) (50) (48)
Fat, Hemangioma 1 (2%)
Stomach, Forestomach (50) (50) (49) (48)
Page 2
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Fibrous Histiocytoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (49) (50) (48) (49)
Fibrous Histiocytoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Tongue (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (49)
Adenoma 1 (2%) 1 (2%)
Fibrous Histiocytoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Adrenal Medulla (50) (49) (50) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 2 (4%) 1 (2%) 1 (2%)
Islets, Pancreatic (48) (49) (50) (48)
Adenoma 1 (2%) 1 (2%)
Pituitary Gland (49) (44) (48) (44)
Pars Distalis, Adenoma 8 (16%) 7 (16%) 6 (13%) 2 (5%)
Pars Intermedia, Adenoma 2 (4%) 1 (2%)
Thyroid Gland (49) (50) (50) (50)
Follicular Cell, Adenoma 2 (4%) 4 (8%) 6 (12%) 2 (4%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (50) (50) (49)
Carcinoma 1 (2%) 1 (2%) 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Ovary (50) (49) (49) (50)
Cystadenoma 3 (6%) 2 (4%) 1 (2%)
Fibrous Histiocytoma 1 (2%)
Page 3
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Granulosa Cell Tumor Benign 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Luteoma 1 (2%)
Uterus (50) (50) (50) (50)
Fibrous Histiocytoma 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leiomyosarcoma 1 (2%)
Endometrium, Carcinoma 1 (2%)
Endometrium, Polyp Stromal 3 (6%) 1 (2%)
Vagina (50) (48) (48) (50)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 5 (10%) 4 (8%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (48)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (8) (7) (4) (6)
Fibrosarcoma, Metastatic, Skin 1 (25%)
Inguinal, Fibrosarcoma, Metastatic, Skin 1 (13%) 1 (25%)
Mediastinal, Carcinoma, Metastatic,
Uncertain Primary Site 1 (17%)
Renal, Hemangiosarcoma 1 (14%)
Lymph Node, Mandibular (46) (46) (48) (44)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (48) (49) (48) (49)
Fibrous Histiocytoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Spleen (49) (49) (49) (49)
Fibrous Histiocytoma 1 (2%)
Hemangiosarcoma 3 (6%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (47) (46) (48) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Thymoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 3 (6%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Vulva, Squamous Cell Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Osteosarcoma 1 (2%)
Skeletal Muscle (47) (50) (49) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 4 (8%) 4 (8%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Carcinoma, Metastatic, Clitoral Gland 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 3 (6%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma 1 (2%)
Mediastinum, Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Mediastinum, Fibrous Histiocytoma 1 (2%)
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%)
Nose (50) (50) (50) (50)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (1)
Carcinoma, Metastatic, Harderian Gland 1 (50%)
Harderian Gland (5) (2) (2) (1)
Adenoma 3 (60%) 2 (100%) 1 (50%) 1 (100%)
Carcinoma 1 (20%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (49)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Urinary Bladder (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant 8 (16%) 12 (24%) 8 (16%) 6 (12%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 44 40 41 39
Total Primary Neoplasms 91 77 74 56
Total Animals with Benign Neoplasms 36 24 24 22
Total Benign Neoplasms 47 33 34 27
Total Animals with Malignant Neoplasms 32 28 33 28
Total Malignant Neoplasms 44 44 40 29
Total Animals with Metastatic Neoplasms 3 1 6 3
Total Metastatic Neoplasm 8 1 12 17
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 10 3 5 10
Moribund Sacrifice 9 11 9 6
Dosing Accident 1 1
Survivors
Terminal Sacrifice 31 35 35 34
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (45) (50) (46) (47)
Carcinoma 1 (2%)
Intestine Small, Ileum (45) (49) (46) (46)
Hemangiosarcoma 1 (2%)
Liver (50) (50) (50) (50)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 3 (6%) 3 (6%) 4 (8%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 15 (30%) 17 (34%) 17 (34%) 14 (28%)
Hepatocellular Carcinoma, Multiple 4 (8%) 7 (14%) 1 (2%) 2 (4%)
Hepatocellular Adenoma 9 (18%) 13 (26%) 13 (26%) 13 (26%)
Hepatocellular Adenoma, Multiple 10 (20%) 4 (8%) 2 (4%) 4 (8%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mesentery (3) (5) (1) (1)
Carcinoma, Metastatic, Islets, Pancreatic 1 (20%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
Pancreas (48) (50) (50) (50)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Stomach, Forestomach (49) (50) (50) (47)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (49) (50) (50) (47)
Carcinoma 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (50)
Adenoma 2 (4%) 2 (4%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Bilateral, Capsule, Adenoma 1 (2%)
Capsule, Adenoma 5 (10%) 3 (6%) 2 (4%)
Adrenal Medulla (48) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%) 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (48) (50) (50) (50)
Carcinoma 1 (2%)
Pituitary Gland (47) (43) (48) (43)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Bilateral, Follicular Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 5 (10%) 2 (4%) 1 (2%) 5 (10%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Seminal Vesicle (50) (50) (50) (49)
Testes (50) (50) (50) (50)
Interstitial Cell, Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (2) (4) (5) (2)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (50%)
Page 9
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mediastinal, Histiocytic Sarcoma 1 (50%)
Pancreatic, Hepatocellular Carcinoma,
Metastatic, Liver 1 (50%)
Lymph Node, Mesenteric (46) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Histiocytic Sarcoma 1 (2%)
Spleen (48) (50) (50) (49)
Hemangiosarcoma 1 (2%) 2 (4%) 4 (8%) 4 (8%)
Thymus (42) (45) (46) (42)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (49) (50) (50)
Subcutaneous Tissue, Fibrosarcoma 2 (4%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
Subcutaneous Tissue, Hepatocellular
Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (50) (50) (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 6 (12%) 7 (14%) 5 (10%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 4 (8%) 3 (6%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Fibrosarcoma 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 3 (6%) 1 (2%) 3 (6%)
Page 10
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1) (1) (1)
External Ear, Histiocytic Sarcoma 1 (100%)
Eye (1) (6) (2)
Retrobulbar, Fibrosarcoma 1 (17%)
Harderian Gland (4) (9) (4) (4)
Adenoma 3 (75%) 9 (100%) 3 (75%) 4 (100%)
Carcinoma 1 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (50) (50)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Carcinoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant 2 (4%) 3 (6%) 6 (12%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 89006-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC AZT/INTERFERON A/INTERFERON AD Date: 07/12/96
Route: GAVAGE Time: 15:15:19
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120MG/KG
CONTROL 5000 U 5000 U 5000 U
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 41 44 40 43
Total Primary Neoplasms 67 91 73 71
Total Animals with Benign Neoplasms 28 30 26 31
Total Benign Neoplasms 37 45 31 39
Total Animals with Malignant Neoplasms 28 34 29 26
Total Malignant Neoplasms 30 46 42 32
Total Animals with Metastatic Neoplasms 7 5 2 5
Total Metastatic Neoplasm 7 16 2 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------